BRIEF-Olema Oncology Announces New Clinical Trial Collaboration And Supply Agreement With Novartis In Frontline Metastatic Breast Cancer As Well As $250 Million Equity Private Placement

Reuters

2024-12-02

BRIEF-Olema Oncology Announces New Clinical Trial Collaboration And Supply Agreement With Novartis In Frontline Metastatic Breast Cancer As Well As $250 Million Equity Private Placement

Dec 2 (Reuters) - Olema Pharmaceuticals OLMA.O:

OLEMA ONCOLOGY ANNOUNCES NEW CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH NOVARTIS IN FRONTLINE METASTATIC BREAST CANCER AS WELL AS $250 MILLION EQUITY PRIVATE PLACEMENT
OLEMA PHARMACEUTICALS INC - WELL CAPITALIZED TO FUND OPERATIONS BEYOND KEY MILESTONES

Source text: ID:nGNX5SNQcx

Further company coverage: OLMA.O

((Reuters.Briefs@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2488780356"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2488780356\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2488780356?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-02 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488780356","market":"us","top_or_hot":-1,"title":"BRIEF-Olema Oncology Announces New Clinical Trial Collaboration And Supply Agreement With Novartis In Frontline Metastatic Breast Cancer As Well As $250 Million Equity Private Placement","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Olema Oncology Announces New Clinical Trial Collaboration And Supply Agreement With Novartis In Frontline Metastatic Breast Cancer As Well As $250 Million Equity Private Placement</title></head><body><p><span>Dec 2 (Reuters)</span><span> - </span>Olema Pharmaceuticals <span>OLMA.O</span>:</p><ul><li><p>OLEMA ONCOLOGY ANNOUNCES NEW CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH NOVARTIS IN FRONTLINE METASTATIC BREAST CANCER AS WELL AS $250 MILLION EQUITY PRIVATE PLACEMENT</p></li><li><p>OLEMA PHARMACEUTICALS INC - WELL CAPITALIZED TO FUND OPERATIONS <a href=\"https://laohu8.com/S/BYON\">BEYOND</a> KEY MILESTONES</p></li></ul><p>Source text: <span>ID:nGNX5SNQcx</span></p><p>Further company coverage: <span>OLMA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Olema Oncology Announces New Clinical Trial Collaboration And Supply Agreement With Novartis In Frontline Metastatic Breast Cancer As Well As $250 Million Equity Private Placement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Olema Oncology Announces New Clinical Trial Collaboration And Supply Agreement With Novartis In Frontline Metastatic Breast Cancer As Well As $250 Million Equity Private Placement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-12-02 20:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Olema Oncology Announces New Clinical Trial Collaboration And Supply Agreement With Novartis In Frontline Metastatic Breast Cancer As Well As $250 Million Equity Private Placement</title></head><body><p><span>Dec 2 (Reuters)</span><span> - </span>Olema Pharmaceuticals <span>OLMA.O</span>:</p><ul><li><p>OLEMA ONCOLOGY ANNOUNCES NEW CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH NOVARTIS IN FRONTLINE METASTATIC BREAST CANCER AS WELL AS $250 MILLION EQUITY PRIVATE PLACEMENT</p></li><li><p>OLEMA PHARMACEUTICALS INC - WELL CAPITALIZED TO FUND OPERATIONS <a href=\"https://laohu8.com/S/BYON\">BEYOND</a> KEY MILESTONES</p></li></ul><p>Source text: <span>ID:nGNX5SNQcx</span></p><p>Further company coverage: <span>OLMA.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241202:nTUA7MHVLF:1","article_id":"2488780356","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488780356","pubTimestamp":1733141096,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Olema Oncology Announces New Clinical Trial Collaboration And Supply Agreement With Novartis In Frontline Metastatic Breast Cancer As Well As $250 Million Equity Private PlacementDec 2 (Reuters)","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4505":"高瓴资本持仓","OLMA":"Olema Pharmaceuticals, Inc."},"translate_title":"简介-Olema Oncology宣布与诺华在一线转移性乳腺癌领域达成新的临床试验合作和供应协议，并进行2.5亿美元的股权私募","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OLMA":0.9},"content_text":"BRIEF-Olema Oncology Announces New Clinical Trial Collaboration And Supply Agreement With Novartis In Frontline Metastatic Breast Cancer As Well As $250 Million Equity Private PlacementDec 2 (Reuters) - Olema Pharmaceuticals OLMA.O:OLEMA ONCOLOGY ANNOUNCES NEW CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH NOVARTIS IN FRONTLINE METASTATIC BREAST CANCER AS WELL AS $250 MILLION EQUITY PRIVATE PLACEMENTOLEMA PHARMACEUTICALS INC - WELL CAPITALIZED TO FUND OPERATIONS BEYOND KEY MILESTONESSource text: ID:nGNX5SNQcxFurther company coverage: OLMA.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,corporation","news_rank":0,"symbols":[],"gpt_button":1}}}